Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,680,917 papers from all fields of science
Search
Sign In
Create Free Account
meproscillarin
Known as:
3Beta-((6-Deoxy-4-O-Methyl-Alpha-L-Mannopyranosyl)Oxy)-14-Hydroxybufa-4,20,22-Trienolide
, methylproscillaridin
, proscillaridin 4'-methyl ether
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Proscillaridin
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
Are all cardiac glycosides pharmacodynamically similar?
P. Joubert
European Journal of Clinical Pharmacology
2004
Corpus ID: 35933781
Cardiac glycosides are used clinically because of two important pharmacological properties, namely positive inotropism in the…
Expand
1986
1986
Determination of proscillaridin in plasma by radioimmunoassay.
K. Kojima
,
K. Yamamoto
,
Y. Terauchi
,
A. Kagemoto
,
S. Naruto
,
Y. Nakanishi
Journal of Pharmacobio-Dynamics
1986
Corpus ID: 39693983
The development of a sensitive and selective radioimmunoassay for determination of proscillaridin in plasma is described…
Expand
1979
1979
[Meproscillarin in patients with renal failure and concomitant heart failure (author's transl)].
H. Beckmann
,
G. Belz
,
E. Quellhorst
Medizinische Klinik
1979
Corpus ID: 23326075
Meproscillarin is a glycoside with a high bioavailability (about 70%) and an elimination independent of the renal function. It…
Expand
1978
1978
[Elimination rate of meproscillarin following repeated application in patients with reduced renal function (author's transl)].
H. Beckmann
,
G. Belz
,
E. Quellhorst
Arzneimittel-Forschung
1978
Corpus ID: 20411253
It was to be investigated whether the elimination rate of 14-hydroxy-3beta-[(4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa…
Expand
1978
1978
[On the possible meproscillarin accumulation in patients with impaired renal function (author's transl)].
W. Twittenhoff
,
W. Brittinger
,
D. Deckert
,
G. Belz
,
I. Schubert
Arzneimittel-Forschung
1978
Corpus ID: 41584622
26 patients with impaired renal function and 7 healthy subjects received an oral dose of 0.5 mg 14-Hydroxy-3-beta-[(4-O-methyl…
Expand
1977
1977
Die Wirkung von Proscillaridin-4′-methyläther auf die maximale Druckanstiegsgeschwindigkeit im linken Ventrikel von Patienten mit Coronarinsuffizienz
M. Stauch
,
N. Grewe
,
G. Belz
Klinische Wochenschrift
1977
Corpus ID: 24172312
SummaryIn a randomized, controlled, double-blind study 2 groups of 7 patients each with coronary heart disease received either 1…
Expand
1975
1975
Metabolism and excretion of methylproscillaridin by man
N. Rietbrock
,
R. Staud
European Journal of Clinical Pharmacology
1975
Corpus ID: 22835334
Summary0.5 mg3H-proscillaridin-4-methylether was administered orally to 5 healthy males. Maximum plasma levels of total…
Expand
1974
1974
Glykosidplasmaspiegel und Elektrokardiogramm nach einmaliger intravenöser und oraler Applikation von Methylproscillaridin bei gesunden Probanden
G. Belz
,
G. Belz
,
H. Schreiter
1974
Corpus ID: 78478165
Das Herzglykosid Proscillaridin weist eine Abklingquote von 30% taglich auf. Bei Untersuchung der Plasmaspiegel dieses Glykosids…
Expand
1974
1974
Plasmakonzentrationen und Elimination von Methylproscillaridin bei Niereninsuffizienz
G. Belz
,
H. Nübling
,
P. Schmidt-Wiederkehr
,
H. Franz
Klinische Wochenschrift
1974
Corpus ID: 20382536
SummaryEight patients with renal insufficiency (creatinine clearance: 0 to 61.2 ml/min/1.73 m2) and six healthy subjects received…
Expand
1974
1974
Effect of oral charcoal on plasma levels of intravenous methyl proscillaridin
G. Belz
,
H. Bader
Klinische Wochenschrift
1974
Corpus ID: 10810002
SummarySix healthy volunteers received 1.0 mg of methyl proscillaridin intravenously two times at a 21 day interval. During one…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE